Description
Methandienone
Strength: 10 mg
Molecular Formula: C20H28O2
Molecular Weight: 300.441 g/mol
Active Ingredient: Methandienone
CAS number: 72-63-9
Dosage Form: Tablet
Route: Oral
Market Status: Prescription
Company: Hilma Biocare
DESCRIPTION
Methandienone 10 is a 17 – alkylated oral steroid that exerts its effects through the androgen
receptor. Methandienone acts on the androgen receptor which results in increased protein
synthesis and nitrogen retention within muscle cells resulting in dramatic increases in
strength and muscle mass.
INDICATIONS
To rapidly restore muscle tissue atrophied during recovery from a traumatic injury. To offset
muscle catabolism in patients with a wasting syndrome. To treat certain types of anemia
which are non-responsive to first line agents.
CLINICAL PHARMACOLOGY
Anabolic steroids are synthetic derivatives of testosterone Certain clinical effects and
adverse reactions demonstrate the androgenic properties of these drugs. Complete
dissociation of anabolic and androgenic effects has not been achieved. The actions of
anabolic steroids are thus similar to those of male sex hormones. Anabolic steroids suppress
the gonadotropic functions of the pituitary and may exert a direct effect upon the testes.
During exogenous administration of anabolic androgens, endogenous testosterone release
is inhibited through inhibition of pituitary luteinizing hormone (LH). At large doses,
spermatogenesis may be suppressed through feedback inhibition of pituitary
follicle-stimulating hormone (FSH). Methandienone has been 17- alkylated to reduce liver
clearance making it practical for oral dosing. Methandienone acts directly on androgen
receptors resulting in increased nitrogen retention and protein synthesis. Methandienone is
subject to aromatization yielding estrogenic side effects if not offset with an aromatase
inhibitor. Methandienone metabolism is hepatic with a half-life of 4.5 to 6 hours.
CONTRAINDICATIONS
Not indicated for women, children, or the elderly. Patients with diagnosed or suspected male
breast carcinoma or carcinoma of the prostate. Patients with diagnosed or suspected female
breast carcinoma with hypercalcemia as androgenic agents may increase osteolytic bone
resorption. Women who are pregnant or may become pregnant because of possible
masculinization of the fetus. Patients with nephrosis or the nephrotic phase of nephritis.
Patients with hypercalcemia. Patients with pre-existing cardiac, renal, and/or hepatic
disease. This product is hepatotoxic and requires Hepatic Monitoring. Discontinue if
jaundicing presents.
PRECAUTIONS
Elevated liver enzymes and in extreme cases hepatic liver dysfunction may occur. 17-
alpha-alkylated androgens may cause cholestatic hepatitis and jaundice, particularly with
larger dosages or prolonged treatment. Liver function should be monitored for changes
including serum bilirubin, aspartate aminotransferase (AST) alanine aminotransferase (ALT),
and alkaline phosphatase (AP). Edema may be increased in patients on concurrent adrenal
cortical steroid or ACTH therapy. Anabolic steroid hormones may increase low-density
lipoproteins (LDL) and decrease high density lipoproteins (HDL). Lipids levels generally
return to normal upon discontinuation of treatment. Anabolic steroids may reduce clotting
factors II, V, VII, and X, and may increase prothrombin time (Pf). Patients should be
instructed to report any use of warfarin and any irregular bleeding. Periodic liver function
tests should be conducted given the association of 17-alpha- alkylated androgens with
hepatotoxicity.
DRUG INTERACTIONS
Oral hypoglycemic agents: may inhibit the metabolism of oral hypoglycemic agents which
may require adjustment of dosage. Anticoagulants: Patients on anticoagulants should be
carefully monitored during anabolic steroid therapy as anabolic steroids may increase
sensitivity to oral anticoagulants. Patients should be monitored regularly during anabolic
steroid therapy, particularly during initiation and termination of therapy.
ADVERSE REACTIONS
Male: Gynecomastia, excessive frequency and duration of penile erections, oligospermia.
Skin and Appendages: Hirsutism, male pattern baldness and acne, gynecomastia.
Fluid/electrolyte Disturbances: Retention of sodium, chloride, water, potassium, calcium, and
inorganic phosphates.
Gastrointestinal: Nausea, cholestatic jaundice, alterations in liver function tests; rarely,
hepatocellular neoplasms, peliosis hepatitis, hepatic adenomas, and cholestatic hepatitis.
Hematologic: Suppression of clotting factors II, V, VII, & X: bleeding in patients on anticoagulant therapy.
Nervous System: Changes in libido, aggression, headache, anxiety, depression, and
generalized paresthesia.
Metabolic: reduced glucose tolerance, increased creatinine clearance, and inhibition of
gonadotropin secretion.
Other: Serum lipid changes, hypercalcaemia, hypertension,oedema, priapism, and
potentiation of sleep apnea.
PATIENT MONITORING
Serum Cholesterol, HDL, LDL. TG. Hemoglobin and Hematocrit, Hepatic function tests –
AST/ALT. Prostatic specific antigen – PSA, Testosterone: total, free, and bioavailable.
Dihydrotestosterone & Estradiol. Male patients over 40 should undergo a digital rectal
examination and evaluate PSA prior to androgen use. Periodic evaluations of the prostate
should continue while on ish androgen therapy, especially in patients with difficulty in
urination or with changes in voiding habits.
DOSAGE AND ADMINISTRATION
Adult males: 10 – 30mg taken orally per day in divided doses for a duration of 3 to 6 weeks.
PRESENTATION
Methandienone 10 mg uncoated tablets: 100 tablets in 1 bottle.
STORAGE
Store in a cool dry place between 15 – 25°C, Protect from light.
Reviews